IDEAYA Biosciences Announces IND Submission for IDE892, a Potential Best In Class PRMT5 Inhibitor for MTAP Deletion Solid Tumors

Wednesday, September 3, 2025 1 min read

Key Takeaway: IDEAYA Biosciences Announces IND Submission for IDE892, a Potential Best In Class PRMT5 Inhibitor for MTAP Deletion Solid Tumors

Full Press Release Details

IDEAYA Biosciences Announces IND Submission for IDE892, a Potential Best In Class PRMT5 Inhibitor for MTAP Deletion Solid Tumors.